Understanding ‘evergreening’: making minor modifications of existing medications to extend protections

17 May 2022 - Recent studies have examined strategic behaviours in the pharmaceutical industry that extend patent and regulatory protection, known ...

Read more →

Pfizer settles two lawsuits, starts another over etanercept biosimilar in Australia

17 May 2022 - After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit ...

Read more →

Leaked TRIPS proposal misguided about improving global COVID-19 vaccination rates

24 March 2022 - The leaked proposal on the waiver on intellectual property rights for COVID-19 vaccines is misguided and ...

Read more →

Catalyst Pharmaceuticals and KYE Pharmaceuticals announce a second favourable Canadian Federal Court ruling setting aside approval of Ruzurgi

11 March 2022 - Catalyst Pharmaceuticals and KYE Pharmaceuticals today announced receipt of a favourable decision from the Federal Court of ...

Read more →

Updating the Bayh-Dole Act; march-in rights and transparency

24 February 2022 - The Patent and Trademark Law Amendments Act (Bayh-Dole Act [35 USC §200-212]) was enacted in 1980 and ...

Read more →

MTAA welcomes patent box legislation

11 February 2022 - MTAA has welcomed the introduction of the Government’s Patent Box Bill into the House of Representatives ...

Read more →

Patent box legislation to promote Australian innovation

11 February 2022 - Medicines Australia notes the introduction of patent box legislation, Treasury Laws Amendment (Tax Concession for Australian ...

Read more →

Pfizer pushes to intervene in lawsuit seeking COVID vaccine information from FDA

27 January 2022 - Pfizer wants to intervene in a Texas federal lawsuit seeking information from the U.S. FDA used ...

Read more →

Patent thickets are thwarting U.S. availability of lower cost biosimilar medicines, study finds

18 January 2022 - Amid debate over competition in the pharmaceutical industry, a new analysis found just 6% of patents ...

Read more →

Data protection scheme for assessed listed medicines

29 September 2021 - The TGA has implemented a data protection scheme for assessed listed medicines.  ...

Read more →

Medicines Australia and AusBiotech say COVID-19 vaccine patent waiver will not speed up global vaccination

15 September 2021 - Medicines Australia and AusBiotech, the peak bodies representing the Australian innovative pharmaceutical and biotechnology sectors, urge ...

Read more →

A court decision on “skinny labeling” another challenge for less expensive drugs

13 September 2021 - Brand name drugs, such as apixaban (Eliquis) and lenalidomide (Revlimid), account for approximately 80% of US drug ...

Read more →

Reimagining pharmaceutical market exclusivities: should the duration of guaranteed monopoly periods be value based?

13 September 2021 - The amount of time in which brand pharmaceutical markets are protected does not correspond with the products’ ...

Read more →

Joint statement of support for an Australian Patent Box

13 September 2021 - Australia’s health innovators support the introduction of a Patent Box, and we welcome this initiative by the ...

Read more →

FDA orphan drug approval: Octapharma’s Octagam 10% receives 7 years of market exclusivity for adult dermatomyositis

30 August 2021 - Octagam 10% expected to become the first treatment option for adults with rare immune-mediated inflammatory disease. ...

Read more →